Detalles de la búsqueda
1.
Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome.
Br J Clin Pharmacol
; 83(8): 1782-1790, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28239897
2.
Do Double-Expressor High-Grade B-Cell Lymphomas Really Need Intensified Treatment? A Report from the Real-Life Series of High-Grade B-Cell Lymphomas Treated with Different Therapeutic Protocols at the Institute of Oncology Ljubljana.
Biomedicines
; 12(2)2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38397877
3.
Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma.
Oncol Lett
; 24(3): 320, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35949614
4.
The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients.
Oncol Lett
; 11(5): 3332-3336, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27123112
5.
Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy.
Leuk Lymphoma
; 53(10): 1945-8, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22563814
Resultados
1 -
5
de 5
1
Próxima >
>>